MedTrace Logo

Evaluation of Etomidate on Adrenal Function in Trauma Patients

NCT00462644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-02-23

Study results available
· View outcomes & findings →

Summary

Trauma patients are at increased risk for adrenal function insufficiency. A commonly used agent for rapid sequence intubation (RSI) is known to decrease adrenal function. We want to determine the incidence of adrenocortical insufficiency and its significance during the first 24 hours of resuscitation following RSI in trauma patients.

Conditions

Interventions

DRUG

RSI sedation with etomidate/succinylcholine

etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV

DRUG

RSI sedation with fentanyl/midazolam/succinylcholine

100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Vicente A Mejia, MD · University of Tennessee

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-08-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00462644 on ClinicalTrials.gov